Waskyra is the first FDA-approved gene therapy for the rare disease Wiskott-Aldrich syndrome and the first such approved product from a non-profit applicant, Fondazione Telethon. Data from Waskyra’s pivotal studies were presented this week during the annual meeting of the American Society of Hematology.
The post FDA Flexibility Leads to First Approved Gene Therapy for Rare Blood & Immune System Disorder appeared first on MedCity News.
